Summary
Heart failure is now viewed as a disorder of the circulation, not merely the heart, which becomes manifest only when certain compensatory mechanisms break down. After treatment with diuretics, the two main strategies in treating heart failure involve decreasing the work of the heart by vasodilatation or increasing ventricular contractility by positive inotropic agents. It is now apparent, however, that the resulting hemodynamic benefit need not equate with long-term clinical improvement or increased longevity; indeed, the reverse can be true. Inhibitors of phosphodiesterase III, which is specific for the breakdown of cyclic adenosine monophosphate (cAMP), produce useful hemodynamic effects following intravenous and oral dosing, but have not fulfilled their initial promise in the chronic oral treatment of heart failure patients. The reason for reduced survival in the long-term studies of milrinone is not clear, but cardiac arrhythmias, possibly resulting from the increased intracellular levels of cAMP, may be responsible. However, intravenous usage may not suffer from the same limitations as chronic oral dosing. Short-term intravenous administration produces the expected beneficial hemodynamic effects of positive inotropism and vasodilatation. Though infusions of milrinone have been shown to enhance atrioventricular conduction in some, but not all, studies, there appears to be no significant increase in ventricular premature contractions, or ventricular or sustained tachyarrhythmias. Because milrinone does not have a significant adverse effect on His-Purkinje conduction, its use should be well tolerated in patients with intraventricular conduction disturbances. However, accurate assessment of the mortality risk and benefit of short-term intravenous treatment remains to be made in sufficiently powerful prospective, randomized controlled studies. In the meantime, PDE III inhibitors may be suitable for short-term intravenous administration in carefully selected and monitored heart failure patients requiring short-term inotropic support, including potential cardiac transplant patients awaiting surgery.
Similar content being viewed by others
References
Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.N Engl J Med 1986;314:1547–1552.
Franciosa JA, Jordan RA, Wilen MM, Leddy CL. Minoxidil in patients with left heart failure: Contrasting hemodynamic and clinical effects in a controlled trial.Circulation 1984;70:63–69.
Yusuf S, Teo K. Inotropic agents increase mortality in patients with congestive heart failure (abstr.)Circulation 1990;82(Suppl):673.
Opie LH, Inodilators.Lancet 1986;1:1336.
Simonton CA, Chatterjee K, Cody RJ, et al. Milrinone in congestive heart failure: Acute and chronic hemodynamic and clinical evaluation.J Am Coll Cardiol 1985;6:453–459.
Packer M, Carver JR, Rodeheffer RJ, et al. Effect of milrinone on mortality in severe chronic heart failure.N Engl J Med 1991;325:1468–1475.
Uretsky BF, Jessup M, Konstam MA, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: Lack of benefit compared with placebo.Circulation 1990;82:774–780.
Goldberg AD, Goldstein S, Nicklas J. Multicenter trial of imazodan in patients with chronic congestive heart failure.Circulation 1990;82(Suppl III):III673.
Silver PJ. Biochemical aspects of inhibition of cardiovascular low Km cAMP phosphodiesterase.Am J Cardiol 1989;63:2A-8A.
Evans DB. Overview of cardiovascular physiologic and pharmacologic aspects of selective phosphodiesterase peak III inhibitors.Am J Cardiol 1989;63:9A-11A.
Strada SJ, Thompson WJ. Cyclic nucleotide phosphodiesterases.Adv Cyclic Nucl Prot Phosph Res 1984;16:1.
Lubbe WF, Podzuweit T, Opie LH. Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: Implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors.J Am Coll Cardiol 1992;19:1622–1633.
Sys S, Goenen MJ, Chalant CH, Brutsaert DL. Inotropic effects of amrinone and milrinone on contraction and relaxation of isolated cardiac muscle.Circulation 1986;73(Suppl III):25–35.
Wilmhurst PT, Walker JM, Fry CH, et al. Inotropic and vasodilator effects of amrinone on isolated human tissues.Cardiovasc Res 1984;18:302.
Erdmann E. Effectiveness of inotropic agents in isolated cardiac preparations from the human heart.Klin Wochenschr 1988;66:1–6.
Leier CV. Acute inotropic support. In:Cardiotonic drugs—A Clinical Survey. New York: Marcel Dekker, 1986:72–75.
Farah AE, Frangakis CJ. Studies on the mechanism of action of the bipyridine milrinone on the heart. In: Just H, Holubarsch C, Scholz, ed. Inotropic Stimulation and Myocardial Energetics.Basic Res Cardiol 1989;84:85–103.
Mylotte KM, Cody V, Davis PJ, et al. Milrinone and thyroid hormone stimulate myocardial membrane Ca2+-ATPase activity and share structural homologies.Proc Natl Acad Sci USA 1985;82:7974–7978.
Monrad ES, McKay RG, Baim DS, et al. Improvement in indices of diastolic performance in patients with congestive heart failure treated with milrinone.Circulation 1984;70:1030–1037.
Piscione F, Jaski BE, Wentling GJ, et al. Effect of a single oral dose of milrinone on left ventricular diastolic performance in the failing human heart.J Am Coll Cardiol 1987;10:1294–1302.
DeFeo TT, Morgan KG. Mechanism of potent vasodilatory effects of milrinone.Circulation 1985;72(part 2)312.
Kauffman RF, Schenck KW, Utterback BG, et al. In vitro vascular relaxation by new inotropic agents: Relationship to phosphodiesterase inhibition and cyclic nucleotides.J Pharmacol Exp Ther 1987;242:864–872.
Harris AL, Silver PJ, Lemp BM, et al. The vasorelaxant effects of milrinone and other vasodilators are attenuated by ouabain.Eur J Pharmacol 1988;145:133–139.
Young RA, Ward A. Milrinone: A preliminary review of its pharmacological properties and therapeutic use.Drugs 1988;36:158–192.
Irisawa H, Noma A. Origin and regulation of cardiac rhythmicity. In: Rupp H, ed.The Regulation of Heart Function. New York: Thieme, 1986;95–105.
Podzuweit T, Lubbe WF, Opie LH. Cyclic adenosine monophosphate, ventricular fibrillation and antiarrhythmic drugs.Lancet 1976;1:341–342.
Podzuweit T, Dalby AJ, Cherry GW, Opie LH. Cyclic AMP levels in ischaemic and nonischaemic myocardium following coronary artery ligation: Relation to ventricular fibrillation.J Mol Cell Cardiol 1978;10:81–94.
Lubbe WF, Podzuweit T, Daries P, Opie LH. The role of cyclic adenosine monophosphate in adrenergic effects on ventricular vulnerability to fibrillation in the isolated perfused rat heart.J Clin Invest 1978;61:1260–1269.
Trolese-Mongheal Y, Barthelemy J, Paire M, Duchene-Marullaz P. Arrhythmogenic potencies of amrinone and milrinone in unanaesthetised dogs with myocardial infarct.Gen Pharmacol 1992;23:95–104.
Piwonka RW, Healey JF, Canniff PC, Farah AE. Electrophysiological actions of amrinone in dogs with cardiac lesions.J Cardiovasc Pharmacol 1983;5:1052–1057.
Lynch JJ, Uprichard ACG, Frye JW, et al. Effects of the positive inotropic agents milrinone and pimobendan on the development of lethal ischemic arrhythmias in conscious dogs with recent myocardial infarction.J Cardiovasc Pharmacol 1989;14:585–596.
Holbrok M, Coker SJ. Comparison of the effects of isobutyl-methylxanthine and milrinone on ischaemia-induced arrhythmias and platelet aggregation in anaesthetized rabbits.Br J Pharmacol 1989;98:318–324.
Ludmer PL, Bairn DS, Antman EM, et al. Effects of milrinone on complex ventricular arrythmias in congestive heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy.Am J Cardiol 1987;59:1351–1355.
Anderson JL Askins JC, Gilbert EM, et al. Occurrence of ventricular arrhythmias in patients receiving acute and chronic infusions of milrinone.Am Heart J 1986;111:466–474.
Goldstein RA, Geraci SA, Gray EL, et al. Electrophysiologic effects of milrinone in patients with congestive heart failure.Am J Cardiol 1986;57:624–628.
Holmes JR, Kubo SH, Cody RJ, Klugfield P. Milrinone in congestive heart failure: Observations on ambulatory arrhythmias (abstr).Circulation 1986;74(Suppl II)II-I.
Ferrick KJ, Fein SA, Ferrick AM, et al. Effects of milrinone on ventricular arrhythmias in patients with congestive heart failure (abstr)Circulation 1986;74(Suppl II)II-508.
Ludmer PL, Bairn DS, Gauthier DF, et al. Effects of milrinone on complex ventricular arrhythmias in congestive heart failure (abstr)Circulation 1985;72(Suppl III):III-405.
Kubo SH, Cody RJ, Chatterjee K, et al. Acute dose range study of milrinone in congestive heart failure.Am J Cardiol 1985;55:726–730.
DiBianco R. Acute positive inotropic intervention: The phosphodiesterase inhibitors.Am Heart J 1991;121:1871–1875.
Naccarelli GV, Goldstein RA. Electrophysiology of phosphodiesterase inhibitors.Am J Cardiol 1989;63:35A-40A
Pflugfelder PW, O'Neill BJ, Ogilvie RI, et al. A Canadian multicentre study of a 48 h infusion of milrinone in patients with severe heart failure.Can J Cardiol 1991;7:45–10.
Colucci WS, Wright RJ, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical development.N Engl J Med 1986;314:349–358.
Packham MA, Mustard JF. Pharmacology of platelet-affecting drugs.Circulation 1980;62(Suppl V):26–41.
Haerem JW. Platelet aggregates in intramyocardial vessels of patients dying suddenly and unexpectedly of coronary artery disease.Atherosclerosis 1972;15:199–213.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cruickshank, J.M. Phosphodiesterase III inhibitors: Long-term risks and short-term benefits. Cardiovasc Drug Ther 7, 655–660 (1993). https://doi.org/10.1007/BF00877818
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00877818